Lupin To Draw On Efficiencies As Japan Pricing Pressures Build
Executive Summary
Pricing pressure in Japan is expected to weigh significantly on growth even in the generics segment, putting the focus on manufacturing and R&D efficiencies to sustain progress in this market, according to senior Lupin executives.
You may also be interested in...
Lupin Hit By US Settlement, Japan Injectables Selloff
Despite 10% revenue growth, Lupin ended up with a second-quarter loss from a one-time charge from settling a US lawsuit and the sale of its Japan injectables business. The firm is now counting on levothyroxine and secnidazole to carry it through the next few quarters, amid speculation that it might divest its Japanese subsidiary.
Lupin Q2 Hit By US Settlement, Japan Injectables Selloff
Despite 10% revenue growth, Lupin ends up with a second-quarter loss from a one-time charge from settling a US lawsuit and the sale of its Japan injectables business. It's now counting on levothyroxine and secnidazole to carry it through the next few quarters, amid speculation that it might divest its Japanese subsidiary.
Lupin Rationalizes Japan Operations, Sheds Injectables Business
Lupin sells Japanese injectables business, eight years after it made an acquisition in that segment there. The Indian firm now plans to concentrate on building a hybrid pharma model in the country.